其中包括急性心肌梗死 acute mycardial infarction ; AMI
平均随访8.2年，共有554名参与者出现致死性和非致死性心血管事件，包括心肌梗死、卒中、冠心病和心力衰竭。
Over an average of 8.2 years of follow-up, 554 participants experienced fatal and nonfatal cardiovascular events, including myocardial infarction, stroke, coronary artery disease, and heart failure.
主要终点比较心血管不良事件，这些事件包括病人死亡的首要原因、非致死的心肌梗死、非致死的脑卒中。
Main outcome Measures Adverse cardiovascular outcomes, including the primary outcomes which was the first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke.
结论在近期有过一次急性冠脉综合征的患者中，利伐沙班降低了包括心血管原因所致死亡、心肌梗死或卒中的复合终点的发生危险。
CONCLUSIONS in patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke.
应用推荐